Type 1 interferons: A target for Immune-mediated inflammatory diseases (IMIDs)
Mathian A. et al, (2025), Revue du rhumatisme (edition francaise)
Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology.
Carter LM. et al, (2024), Ann rheum dis
Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).
Mathian A. et al, (2023), Joint bone spine, 91
A cellular overview of immunometabolism in systemic lupus erythematosus
Psarras A. and Clarke A., (2023), Oxford open immunology, 4
Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.
Md Yusof MY. et al, (2023), Rheumatol adv pract, 7
Novel La1−xCaxMnO3 perovskite materials for chemical looping combustion applications
Iliopoulou EF. et al, (2022), International journal of energy research, 46, 20386 - 20400
Anti-BDCA2 Antibody for Cutaneous Lupus Erythematosus.
Psarras A. and Vital EM., (2022), N engl j med, 387, 1528 - 1529
Emerging concepts of type I interferons in SLE pathogenesis and therapy
Psarras A. et al, (2022), Nature reviews rheumatology
Keratinocytes: From passive targets to active mediators of systemic autoimmunity
Psarras A. and Vital EM., (2022), Science translational medicine, 14
Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus
Carter LM. et al, (2022), Arthritis and rheumatology
TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation.
Psarras A. et al, (2021), J immunol, 206, 785 - 796
Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity.
Psarras A. et al, (2020), Nat commun, 11
B Cell Tetherin: A Flow Cytometric Cell‐Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus
El‐Sherbiny YM. et al, (2020), Arthritis & rheumatology, 72, 769 - 779
Engineering the Catalytic Properties of HZSM5 by Cobalt Modification and Post-synthetic Hierarchical Porosity Development
Kantarelis E. et al, (2019), Topics in catalysis, 62, 773 - 785
A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features
El-Sherbiny YM. et al, (2018), Scientific reports, 8
Erratum to: A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features (Scientific Reports, (2018), 8, 1, (5793), 10.1038/s41598-018-24198-1)
El-Sherbiny YM. et al, (2018), Scientific reports, 8
Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status
Md Yusof MY. et al, (2018), Annals of the rheumatic diseases, 77, 1432 - 1439
TNF-alpha Regulates Plasmacytoid Dendritic Cells By Suppressing IFN-alpha Production and Enhancing Th1 and Th17 Cell Differentiation
Psarras A. et al, (2018), Arthritis & rheumatology, 70
Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE
Psarras A. et al, (2018), Arthritis & rheumatology, 70
Type I interferon–mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy
Psarras A. et al, (2017), Rheumatology, kew431 - kew431